PMID- 30087576
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220318
IS  - 1179-1314 (Print)
IS  - 1179-1314 (Electronic)
IS  - 1179-1314 (Linking)
VI  - 10
DP  - 2018
TI  - Single-day HER2neu amplification assessment using chip-based digital PCR in 
      formalin-fixed paraffin-embedded breast carcinoma tissue.
PG  - 121-129
LID - 10.2147/BCTT.S161264 [doi]
AB  - INTRODUCTION: Human epidermal growth factor receptor 2 (HER2) amplification is 
      present in almost 15%-20% of breast cancer tumors, making it an important 
      parameter for testing. The present study was designed to evaluate a chip-based 
      digital PCR (dPCR) system for assessing HER2 amplification from formalin-fixed 
      paraffin-embedded breast carcinoma tissue and to compare this system with 
      immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). 
      MATERIALS AND METHODS: A total of 84 breast carcinoma tissue samples were 
      analyzed by IHC, FISH, and chip-based dPCR in a blinded manner. RESULTS: All nine 
      IHC-positive and 35 IHC-negative samples had equivalent results with dPCR, taking 
      an amplification ratio threshold of 1.8 as a positive result. Of the 40 IHC 
      equivocal samples, 10 were assessed as positive, 27 as negative, and three as 
      equivocal by dPCR. CONCLUSION: These results demonstrate that chip-based dPCR is 
      suitable for HER2 amplification detection in formalin-fixed paraffin-embedded 
      samples in a clinical setting, providing the advantages of superior turnaround 
      time, cost-effectiveness, and increased precision with absolute quantification 
      compared with conventional tests such as FISH and IHC. This methodology was 
      especially beneficial in tissue samples with low DNA concentration.
FAU - Shah, Parth S
AU  - Shah PS
AD  - Department of Molecular Genetics, Supratech Micropath Laboratory and Research 
      Institute, Ahmedabad, India, shiva.murarka@supratechlabs.com.
AD  - Department of Medicine, Lahey Hospital and Medical Center, Burlington, MA, USA.
FAU - Murarka, Shiva
AU  - Murarka S
AD  - Department of Molecular Genetics, Supratech Micropath Laboratory and Research 
      Institute, Ahmedabad, India, shiva.murarka@supratechlabs.com.
FAU - Joshi, Anupam
AU  - Joshi A
AD  - Department of Histopathology, Supratech Micropath Laboratory and Research 
      Institute, Ahmedabad, India.
FAU - Mehta, Bhavna
AU  - Mehta B
AD  - Department of Histopathology, Supratech Micropath Laboratory and Research 
      Institute, Ahmedabad, India.
FAU - Parmar, Vipal
AU  - Parmar V
AD  - Department of Histopathology, Supratech Micropath Laboratory and Research 
      Institute, Ahmedabad, India.
FAU - Shah, Nidhi
AU  - Shah N
AD  - Department of Molecular Genetics, Supratech Micropath Laboratory and Research 
      Institute, Ahmedabad, India, shiva.murarka@supratechlabs.com.
AD  - Department of Pediatrics, Nassau University Medical Center, East Meadow, NY, USA.
FAU - Patel, Khushbu
AU  - Patel K
AD  - Department of Molecular Genetics, Supratech Micropath Laboratory and Research 
      Institute, Ahmedabad, India, shiva.murarka@supratechlabs.com.
FAU - Sands, Jacob
AU  - Sands J
AD  - Department of Hematology and Oncology, Lahey Hospital and Medical Center, 
      Burlington, MA, USA.
LA  - eng
PT  - Journal Article
DEP - 20180723
PL  - New Zealand
TA  - Breast Cancer (Dove Med Press)
JT  - Breast cancer (Dove Medical Press)
JID - 101591856
PMC - PMC6061198
OTO - NOTNLM
OT  - FISH
OT  - HER2
OT  - IHC
OT  - breast cancer
OT  - digital PCR
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/08/09 06:00
MHDA- 2018/08/09 06:01
PMCR- 2018/07/23
CRDT- 2018/08/09 06:00
PHST- 2018/08/09 06:00 [entrez]
PHST- 2018/08/09 06:00 [pubmed]
PHST- 2018/08/09 06:01 [medline]
PHST- 2018/07/23 00:00 [pmc-release]
AID - bctt-10-121 [pii]
AID - 10.2147/BCTT.S161264 [doi]
PST - epublish
SO  - Breast Cancer (Dove Med Press). 2018 Jul 23;10:121-129. doi: 
      10.2147/BCTT.S161264. eCollection 2018.